Floatz logo

IBUPROFEN

Migraine Without Aura

Kecioren Education and Training HospitalSmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Migraine Without Aura cohort.

Asset / SponsorPhaseRating
Topamax
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 4BBB
Dihydroergotamine mesylate
Satsuma Pharmaceuticals, Inc.
Phase 3BBB
PROPRANOLOL
Norwegian University of Science and Technology
Phase 3BB
METOCLOPRAMIDE
Assistance Publique - Hôpitaux de Paris
Phase 4BB
Rimegepant
University of South Florida
Phase 4BB

View all 50 →

Same molecule, other indications

IBUPROFEN is also rated in:

chronic pain syndromeDormant
BBB
Indicative ·
72 / 100
View asset →
migraine disorderDormant
BBB
Indicative ·
72 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →